NO20004251D0 - Humaniserte anti-CEA monoklonale antistoffer med høy affinitet - Google Patents
Humaniserte anti-CEA monoklonale antistoffer med høy affinitetInfo
- Publication number
- NO20004251D0 NO20004251D0 NO20004251A NO20004251A NO20004251D0 NO 20004251 D0 NO20004251 D0 NO 20004251D0 NO 20004251 A NO20004251 A NO 20004251A NO 20004251 A NO20004251 A NO 20004251A NO 20004251 D0 NO20004251 D0 NO 20004251D0
- Authority
- NO
- Norway
- Prior art keywords
- monoclonal antibodies
- high affinity
- humanized anti
- affinity monoclonal
- cea
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G01N33/57565—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/003680 WO1999043817A1 (en) | 1998-02-25 | 1998-02-25 | High affinity humanized anti-cea monoclonal antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20004251D0 true NO20004251D0 (no) | 2000-08-24 |
| NO20004251L NO20004251L (no) | 2000-10-24 |
Family
ID=22266464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004251A NO20004251L (no) | 1998-02-25 | 2000-08-24 | Humaniserte anti-CEA monoklonale antistoffer med høy affinitet |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1056859A1 (no) |
| JP (1) | JP2002504372A (no) |
| AU (1) | AU752494B2 (no) |
| CA (1) | CA2321947A1 (no) |
| IL (1) | IL138022A0 (no) |
| NO (1) | NO20004251L (no) |
| WO (1) | WO1999043817A1 (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003025565A2 (en) * | 2001-09-21 | 2003-03-27 | Caprion Pharmaceuticals Inc. | Preparation of highly-purified plasma membranes |
| KR20130114758A (ko) * | 2005-05-27 | 2013-10-17 | 오스페달레 산 라파엘 에스.알.엘. | Mi-rna를 포함하는 유전자 벡터 |
| MY164647A (en) * | 2011-03-02 | 2018-01-30 | Roche Glycart Ag | Cea antibodies |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CN106749667B (zh) * | 2016-12-04 | 2020-07-14 | 深圳市国创纳米抗体技术有限公司 | 一种抗癌胚抗原的纳米抗体及其应用 |
| CN113906053B (zh) | 2019-06-26 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 抗cea抗体及其应用 |
| CN116724052A (zh) | 2020-08-20 | 2023-09-08 | A2生物治疗股份有限公司 | 用于治疗ceacam阳性癌症的组合物和方法 |
| KR20250140123A (ko) | 2020-08-20 | 2025-09-24 | 에이투 바이오쎄라퓨틱스, 인크. | 메소텔린 양성 암을 치료하기 위한 조성물 및 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5472693A (en) * | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| WO1997042329A1 (en) * | 1996-05-04 | 1997-11-13 | Zeneca Limited | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
-
1998
- 1998-02-25 EP EP98907630A patent/EP1056859A1/en not_active Withdrawn
- 1998-02-25 JP JP2000533557A patent/JP2002504372A/ja active Pending
- 1998-02-25 CA CA002321947A patent/CA2321947A1/en not_active Abandoned
- 1998-02-25 WO PCT/US1998/003680 patent/WO1999043817A1/en not_active Ceased
- 1998-02-25 AU AU63388/98A patent/AU752494B2/en not_active Ceased
- 1998-02-25 IL IL13802298A patent/IL138022A0/xx unknown
-
2000
- 2000-08-24 NO NO20004251A patent/NO20004251L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20004251L (no) | 2000-10-24 |
| AU6338898A (en) | 1999-09-15 |
| AU752494B2 (en) | 2002-09-19 |
| EP1056859A1 (en) | 2000-12-06 |
| WO1999043817A1 (en) | 1999-09-02 |
| IL138022A0 (en) | 2001-10-31 |
| CA2321947A1 (en) | 1999-09-02 |
| JP2002504372A (ja) | 2002-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69920897D1 (de) | Monoklonale antikörper mit verringerter immunisierungsfähigkeit | |
| DK1516629T3 (da) | Humaniseret anti-CD-11a antibodies | |
| PT719859E (pt) | Anticorpo monoclonal anti-alfa v-integrina | |
| FI963004L (fi) | Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita | |
| FI964845L (fi) | CD44v6:n vastaiset monoklonaaliset vasta-aineet | |
| EP1071458A4 (en) | HUMANIZED ANTIBODIES AND CORRESPONDING USES THEREOF | |
| HUP0300841A3 (en) | Agonist anti-trk-c monoclonal antibodies | |
| AU2559799A (en) | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same | |
| DE69828154D1 (de) | Anti-alphavbeta3 humanizierte monoklonale antikörper | |
| DE69738312D1 (de) | Hepatitis b monoklonale antikörper | |
| FI945865A7 (fi) | Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita | |
| AU7072998A (en) | Immunoassays using anti-allotypic monoclonal antibodies | |
| NO20004251D0 (no) | Humaniserte anti-CEA monoklonale antistoffer med høy affinitet | |
| NO981272D0 (no) | Humanisert anti-human-Fas-antistoff | |
| GB9718911D0 (en) | Monoclonal antibodies | |
| FI20011055A0 (fi) | Heveiiniä sitovat monoklonaaliset vasta-aineet | |
| EP1106701A4 (en) | MONOCLONAL ANTIBODY DIRECTED AGAINST DYNAMIC TRYPSIN | |
| NO985281D0 (no) | Monoklonalt antihumant MP52-antistoff | |
| BR1100555B1 (pt) | anticorpos monoclonais humanizados. | |
| ZA99319B (en) | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same. | |
| AU2002300457A1 (en) | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies | |
| GB9615027D0 (en) | Monoclonal antibodies | |
| IL125204A0 (en) | Anti-bacterial monoclonal antibodies | |
| SI0742795T1 (en) | Immuno-stimulatory monoclonal antibodies | |
| GB0003359D0 (en) | Monoclonal antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |